Biotech companies at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

142 biotech companies are at PEGS Europe 2026 — 99 presentations on the program and 1 with a booth in the exhibit hall. Most represented: Zymeworks (3 on the program), Affilogic (2 on the program), Denali Therapeutics (2 on the program). 22 of them have their own page in this guide. As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–13 of 142 organizations

Organization	PEGS Europe 2026 Attendance
Zymeworks
zymeworks.com Biotech Clinical-stage biotech developing multispecific antibodies and antibody-drug conjugates for cancer and inflammatory diseases; created the Azymetric bispecific platform.	Talk Tue Nov 17 2:05pm–2:35pm Next-Generation Tumour-Targeted Masked Cytokines for Enhanced Tolerability and Localised Anti-Tumour Activity Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Tue Nov 17 2:05pm–2:35pm TriTCE Co-Stim: A Differentiated T Cell Engager Platform with Conditional Cis CD28 Co-Stimulation and Transferability to Diverse Targeting Strategies T Cell Engagers Talk Wed Nov 18 9:00am–9:30am Engineering Simultaneous Targeting of IL-4Ra and IL-33 Pathways to Broadly Suppresses Autoimmune Inflammation Biologics for Autoimmune Diseases
Affilogic Nantes, France
affilogic.com Biotech Develops Nanofitins, small non-antibody protein scaffolds, for targeted delivery and therapeutics.	Talk Wed Nov 18 11:15am–11:45am Bus2Brain: A Nanofitin-Based Platform for Targeted Brain Delivery of Oligonucleotide Therapeutics Engineering Next-Generation Conjugates Panel Wed Nov 18 5:00pm–5:30pm Young Scientist Meet Up Plenary · with ETH Zurich Talk Thu Nov 19 11:15am–11:45am Miniaturisation-Driven Acceleration of Expression and Screening Workflows Highly Parallel Protein Discovery Workflows
Denali Therapeutics South San Francisco, CA
denalitherapeutics.com Biotech Develops medicines for neurodegenerative and lysosomal diseases, using its Transport Vehicle platform to carry biologics across the blood–brain barrier.	Talk Thu Nov 19 11:45am–12:15pm Dual Targeting of Transferrin Receptor and CD98hc Enhances Brain Exposure of Large Molecules Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 2:05pm–2:35pm Transferrin Receptor–Mediated Transport Vehicles Enable Delivery of Therapeutic Enzymes to the CNS and Peripheral Tissues Antibodies Against Challenging Targets Panel Thu Nov 19 3:35pm–4:15pm Brain Delivery of Complex Biotherapeutics: Scientific Challenges and Future Opportunities Antibodies Against Challenging Targets
Immatics Tübingen, Germany
immatics.com Biotech Develops TCR-based cell therapies and TCR bispecifics against cancer targets.	Talk Tue Nov 17 8:30am–9:00am Unlocking Target Multiplexing in Solid Cancers with a Novel Single-Chain TCR Bispecific Approach Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Thu Nov 19 8:30am–9:00am Targeting PRAME+ Cancers: Clinical Progress across TCR T Cell Therapy and Bispecific Approaches Next-Generation Immunotherapies Panel Thu Nov 19 3:35pm–4:15pm Clinical Outcomes in Immunotherapy—Where Are We Now? Next-Generation Immunotherapies · with Accession Therapeutics, BioInvent, Dr. Rosell Oncology Institute, Dexeus University Hospital +2 more
Molecular Partners Zurich, Switzerland
molecularpartners.com Biotech Clinical-stage developer of DARPin therapeutics, including T cell engagers and radio-DARPins for cancer.	Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks T Cell Engagers · with Vir Biotechnology Talk Tue Nov 17 2:35pm–3:05pm MP0632, an AND-Gated Switch-DARPin T Cell Engager with CD2 Costimulation for Ovarian Cancer T Cell Engagers Talk Tue Nov 17 5:20pm–5:50pm DARPins for Targeted Alpha Therapy: From Promising MP0712 First-in-Human Data to Opportunities for Next Radio-DARPin Candidates Antibody-Based Therapies
Genmab Copenhagen, Denmark
genmab.com Biotech Danish antibody company developing bispecifics and antibody-drug conjugates, with marketed medicines in oncology.	Talk Wed Nov 18 9:00am–9:30am Generation of a Massive Dataset on VHH:Antigen Stability via High-Throughput (DMS) Experiments Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 6:01pm–6:30pm T Cell Stimulating Vaccines Empower CD3 Bispecific Antibody Therapy in Solid Tumours Advancing Multispecific Antibodies and Combination Therapy to the Clinic
Ichnos Glenmark Innovation New York, NY
iginnovate.com Biotech Develops multispecific antibodies for blood cancers and solid tumours using its BEAT platform.	Talk Thu Nov 19 9:15am–9:30am Lessons in the Development of Multispecific Antibodies as Immune Engagers Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 3:35pm–4:05pm An Integrated End-to-End Workflow for the Production of Drug-Like Multispecific Therapeutic Antibodies Highly Parallel Protein Discovery Workflows
Immunocore Abingdon, UK
immunocore.com Biotech Develops TCR bispecific medicines for cancer and autoimmune disease, with a marketed melanoma therapy.	Talk Tue Nov 17 9:30am–10:00am Engineering Specific and Potent T Cell Engagers Targeting pHLA Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 7:00pm–7:30pm IMC-S118AI: beta-cell Targeted Bispecific for Type 1 Diabetes (T1D) Disease Modification Biologics for Autoimmune Diseases
VERAXA Biotech Heidelberg, Germany
veraxa.com Biotech Develops antibody-drug conjugates and bispecific T cell engagers for cancer, with its lead program in acute myeloid leukemia.	Talk Tue Nov 17 9:00am–9:30am A Conditionally Active, Dual-Targeting BiTAC-TCE with Superior Tumour Selectivity for the Treatment of Solid Tumours T Cell Engagers Talk Wed Nov 18 7:00pm–7:30pm An Avidity-Driven, Dual-Targeting ADC with Superior Tumour Selectivity for the Treatment of Solid Tumours Engineering Next-Generation Conjugates
BioInvent Lund, Sweden
bioinvent.com Biotech Clinical-stage company developing immune-modulating antibodies, including anti-TNFR2 and anti-FcγRIIB antibodies, for cancer.	Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Next-Generation Immunotherapies Talk Thu Nov 19 2:35pm–3:05pm Leveraging TNFR for Antitumour Immunity: Treg Depletion and Myeloid Reprogramming Versus T Cell Co-Stimulation Next-Generation Immunotherapies Panel Thu Nov 19 3:35pm–4:15pm Clinical Outcomes in Immunotherapy—Where Are We Now? Next-Generation Immunotherapies · with Accession Therapeutics, Immatics, Dr. Rosell Oncology Institute, Dexeus University Hospital +2 more
Cullinan Therapeutics Cambridge, MA
cullinantherapeutics.com Biotech Biotech developing T cell engagers and other targeted therapies for autoimmune diseases and cancer.	Talk Wed Nov 18 11:45am–12:15pm A New Frontier for the Treatment of Autoimmune Diseases: T Cell Engager Therapies Targeting CD19 or BCMA Biologics for Autoimmune Diseases Talk Wed Nov 18 4:00pm–4:10pm The Future of T Cell Engagers Plenary Bispecifics, multispecifics and T cell engagersOncology and immunotherapy Panel Wed Nov 18 4:10pm–4:50pm Emerging Modalities and the Future of Antibody Engineering Plenary · with Stanford University, University of Stuttgart, Johnson & Johnson Innovative Medicine Protein and antibody engineering
AT Accession Therapeutics
	Chair Thu Nov 19 2:00pm–2:05pm Chairperson's Remarks Next-Generation Immunotherapies Panel Thu Nov 19 3:35pm–4:15pm Clinical Outcomes in Immunotherapy—Where Are We Now? Next-Generation Immunotherapies · with BioInvent, Immatics, Dr. Rosell Oncology Institute, Dexeus University Hospital +2 more
Alaya.bio
alaya.bio Biotech Develops polymer-based gene delivery to reprogram immune cells inside the body, including in vivo CAR-T therapies.	Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Advances in Immunoengineering Talk Wed Nov 18 9:30am–10:00am A Novel Polymeric Gene Delivery Platform to Precisely Target and Reprogram Cells in vivo for Hematological Malignancies and Beyond Advances in Immunoengineering